By Stephen Nakrosis
Vincerx Pharma has terminated a reverse merger agreement with Oqory and its parent company Vivasor.
The company said Friday it terminated an approved term sheet signed as part of deal after Oqory ended an exclusivity provision. Vincerx said it will explore strategic options.
The agreement would have seen Oqory merge with Vincerx, resulting in a combined company 95% owned by Oroqy equity holders. The deal would also have seen Oqory-designated investors provide $1.5 million of interim financing to Vincerx.
The company said it will review strategic alternatives, including out-licensing, merger and acquisition opportunities, and winding down operations, among other options. Vincerx said it had about $3.9 million in cash as of Feb. 26, and expects to have enough cash to operate late into the second quarter of this year.
Shares of Vincerx closed the market session down 13% at $1.09. The stock plunged 98% in the past year.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
February 28, 2025 16:55 ET (21:55 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。